The overarching goal in seeking continuation of our status as a CCOP member is expansion of the variety and number of cancer treatment and control protocols available to patients of our largely rural service area which represents a minority population underrepresented in research with little opportunity for clinical trial access. Our 30 year track record in accruing patients to these trials and the renewed NCI focus on cancers screening and prevention clinical trials as well as NCI proposed quality care assessment, comparative- and cost-effectiveness outcomes research through the NCORP structure will provide Marshfield Clinic (MC) CCOP with unprecedented enrollment opportunities. Therefore, MC CCOP plans to increase accrual substantially over the next 5 year grant period contributing positively to NCI sponsored clinical research. To achieve these goals the MC CCOP proposes the following specific aims: 1) Engage in adult and pediatric clinical research related to screening, prevention and treatment of cancer appropriate to the population in and around the MC CCOP service area for which robust enrollment is anticipated, supported by historical data of cancer patterns in the MC CCOP service area. 2) Align the MC CCOP to the proposed NCORP model to position us for participation in NCORP studies, anticipated to be highly appropriate to the population residing in the MC CCOP service area;3) Participate in NCI-proposed clinical research focused on examining quality parameters and effectiveness of current oncology care standards as an important strategy to ensure robust enrollment. The MC CCOP model will promote participation in classic phase ll/lll clinical trials and effective engagement of MC CCOP in complex multidisciplinary trials through the use of a patient centered approach that encompasses the full spectrum of cancer care including screening, quality assessment, cancer and symptom prevention, treatment, survivorship and comparative effectiveness research. The overarching significance of achieving these goals is the program's contribution to developing a new standard of clinical care which more fully incorporates research along the entire trajectory of patient care as encountered in daily clinical practice which is consistent with the stated NCI mission.

Public Health Relevance

The proposed NCI-Community Oncology Research program (NCORP) promises expanded patient access to clinical trials. MC CCOP is positioning itself to expand access to these trials in its service area. Clinical trials collaboratively conducted across participating academic and community based institutions are likely to provide sufficiently large data pools across a diverse patient population resulting in strong scientific validity and potentia for improvement in clinical care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA035412-30
Application #
8526747
Study Section
Special Emphasis Panel (ZCA1-SRLB-B (J1))
Program Officer
O'Mara, Ann M
Project Start
1983-09-01
Project End
2015-05-31
Budget Start
2013-06-24
Budget End
2014-05-31
Support Year
30
Fiscal Year
2013
Total Cost
$969,800
Indirect Cost
$323,267
Name
Marshfield Clinic Research Foundation
Department
Type
DUNS #
074776030
City
Marshfield
State
WI
Country
United States
Zip Code
54449
Jacobus, S J; Rajkumar, S V; Weiss, M et al. (2016) Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen. Blood Cancer J 6:e448
Williams, Michael E; Hong, Fangxin; Gascoyne, Randy D et al. (2016) Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol 173:867-75
Cleeland, Charles S; Zhao, Fengmin; Chang, Victor T et al. (2013) The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer 119:4333-40
Rowe, J M; Andersen, J W; Mazza, J J et al. (1995) A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 86:457-62
Kay, N E; Oken, M M; Mazza, J J et al. (1988) Evidence for tumor reduction in refractory or relapsed B-CLL patients with infusional interleukin-2. Nouv Rev Fr Hematol 30:475-8
Krause, D; Lesiak, K; Imai, J et al. (1986) Activation of 2-5A-dependent RNase by analogs of 2-5A (5'-O-triphosphoryladenylyl(2'----5')adenylyl(2'----5')adenosine ) using 2',5'-tetraadenylate (core)-cellulose. J Biol Chem 261:6836-9